Novan Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 16, 2022 06:30 ET
|
Novan, Inc.
– Transformational quarter for Novan, marked by acquisition of EPI Health – – Strongest quarter in total prescriptions for Rhofade increasing 47% from Q1 2021 – – Ongoing activities toward...
Novan to Report First Quarter 2022 Financial Results on May 16, 2022
May 06, 2022 09:00 ET
|
Novan, Inc.
DURHAM, N.C., May 06, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its first quarter 2022 financial results on Monday, May...
Novan to Participate in the Virtual Investor Innovation in Dermatology Spotlight Event
April 20, 2022 09:05 ET
|
Novan, Inc.
DURHAM, N.C., April 20, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced it will participate in the Virtual Investor Innovation in Dermatology...
Novan Announces Late-Breaking Abstract Accepted for Presentation at American Academy of Dermatology’s (AAD) 2022 Annual Meeting
March 24, 2022 09:00 ET
|
Novan, Inc.
DURHAM, N.C., March 24, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that data from its pivotal Phase 3 study of berdazimer gel 10.3% (SB206) for...
Novan, Inc. to Present at Two Upcoming Investor Conferences
March 14, 2022 09:00 ET
|
Novan, Inc.
DURHAM, N.C., March 14, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that Paula Brown Stafford, President and Chief Executive Officer of Novan,...
Novan Acquires EPI Health, a Specialty Dermatology Company
March 11, 2022 06:35 ET
|
Novan, Inc.
– EPI Health promotes four prescription products posting 2021 operating revenue of $17.6 million – – Acquisition forward integrates Novan with complementary commercial infrastructure to drive...
Novan Reports Full Year 2021 Financial Results and Provides Corporate Update
February 22, 2022 07:00 ET
|
Novan, Inc.
– First New Drug Application (NDA) submission targeted in Q4 2022 for lead program SB206 (berdazimer gel 10.3%) for molluscum contagiosum – – Ongoing advancement of priority development pipeline...
Novan to Report Full Year 2021 Financial Results on February 22, 2022
February 15, 2022 09:00 ET
|
Novan, Inc.
DURHAM, N.C., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its full year 2021 financial results on Tuesday, February...
Novan Announces Presentation of Two Posters at the 2022 Winter Clinical Dermatology Conference
January 14, 2022 09:05 ET
|
Novan, Inc.
DURHAM, N.C., Jan. 14, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that data from the Company’s completed Phase 2 and Phase 3 clinical studies of...
Novan to Participate in the Virtual Investor Roundtable Event
November 12, 2021 09:00 ET
|
Novan, Inc.
– Live moderated video webcast discussion among management and Pediatric Dermatology Thought Leader on Wednesday, November 17th at 1:00 PM ET – DURHAM, N.C., Nov. 12, 2021 (GLOBE NEWSWIRE) --...